Epidiolex, Epidyolex(cannabidiol)
Epidiolex, Epidyolex (cannabidiol) is a small molecule pharmaceutical. Cannabidiol was first approved as Epidiolex on 2018-09-28. It is used to treat anxiety, lennox gastaut syndrome, myoclonic epilepsies, and pain in the USA. It has been approved in Europe to treat lennox gastaut syndrome and myoclonic epilepsies. It is known to target transient receptor potential cation channel subfamily A member 1, N-arachidonyl glycine receptor, transient receptor potential cation channel subfamily V member 3, cannabinoid receptor 1, G-protein coupled receptor 55, transient receptor potential cation channel subfamily V member 2, and transient receptor potential cation channel subfamily M member 8.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Epidiolex
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cannabidiol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EPIDIOLEX | Jazz Pharmaceuticals | N-210365 RX | 2018-09-28 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amour cbd | C200263 | 2024-12-08 |
| asystem radical relief gel roll-on 300mg cbd | OTC monograph not final | 2020-03-19 |
| ay bendito - cbd | C200263 | 2024-11-18 |
| ay bendito cbd | C200263 | 2025-03-18 |
| cbd | OTC monograph not final | 2020-02-10 |
| cbd blue light defense spf 30 | C200263 | 2024-12-05 |
| cbd clinic - massage oil - level 1 | OTC monograph not final | 2017-05-15 |
| cbd clinic - massage oil - level 2 | OTC monograph not final | 2017-05-15 |
| cbd clinic - massage oil - level 3 | OTC monograph not final | 2017-05-15 |
| cbd clinic - mild pain therapy | OTC monograph not final | 2016-07-11 |
Show 106 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CANNABIDIOL, EPIDIOLEX, JAZZ PHARMS RES | |||
| 2027-07-31 | ODE-326, ODE-332 | ||
| 2026-10-20 | M-270 | ||
| 2025-09-28 | ODE-216 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Cannabidiol, Epidiolex, Jazz Pharms Res | |||
| 11160795 | 2041-03-01 | U-3233 | |
| 11406623 | 2041-03-01 | U-3233 | |
| 11207292 | 2039-04-26 | DP | U-3235, U-3236, U-3277 |
| 11865102 | 2039-04-26 | DS, DP | U-2781, U-3236, U-3277 |
| 10918608 | 2035-10-13 | U-3071, U-3072, U-3073 | |
| 11065209 | 2035-10-13 | U-3071 | |
| 11096905 | 2035-10-13 | DS, DP | U-2780, U-2781 |
| 11400055 | 2035-10-13 | U-3071 | |
| 9949937 | 2035-06-17 | U-2421 | |
| 9956183 | 2035-06-17 | U-2422, U-2423 | |
| 9956184 | 2035-06-17 | U-2424 | |
| 9956185 | 2035-06-17 | U-2425 | |
| 9956186 | 2035-06-17 | U-2426 | |
| 10092525 | 2035-06-17 | U-2427 | |
| 10111840 | 2035-06-17 | U-2442, U-2443 | |
| 10137095 | 2035-06-17 | U-2454, U-2455 | |
| 10603288 | 2035-06-17 | U-2780, U-2781, U-2782, U-2783 | |
| 10709671 | 2035-06-17 | U-2862 | |
| 10709673 | 2035-06-17 | DP | |
| 10709674 | 2035-06-17 | U-2780, U-2781 | |
| 10849860 | 2035-06-17 | U-2427, U-2454 | |
| 10966939 | 2035-06-17 | DP | U-2780, U-2781 |
| 11154516 | 2035-06-17 | U-3235, U-3236 | |
| 11311498 | 2035-06-17 | U-3375, U-3376 | |
| 11357741 | 2035-06-17 | U-2862 | |
| 11446258 | 2035-06-17 | U-2780, U-2781, U-3071 | |
| 11633369 | 2035-06-17 | DP | U-2780, U-2781, U-3071 |
| 11701330 | 2035-06-17 | U-2780, U-2781 | |
| 11766411 | 2035-06-17 | U-2781 | |
HCPCS
No data
Clinical
Clinical Trials
1013 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 14 | 1 | 1 | 16 |
| Sclerosis | D012598 | — | — | — | — | 13 | 1 | — | 14 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 5 | 6 | 1 | 1 | 13 |
| Muscle spasticity | D009128 | — | — | — | 1 | 9 | 1 | — | 11 |
| Seizures | D012640 | — | G40.4 | — | — | 4 | 3 | 2 | 9 |
| Myoclonic epilepsies | D004831 | EFO_1001900 | G40.4 | — | 1 | 4 | 2 | 1 | 8 |
| Lennox gastaut syndrome | D065768 | — | G40.81 | — | — | 3 | 3 | 1 | 7 |
| Tuberous sclerosis | D014402 | — | Q85.1 | — | — | 3 | 2 | 1 | 6 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 1 | — | 1 |
| Behavior | D001519 | GO_0007610 | STY/T053 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | — | 14 | — | — | 14 |
| Neoplasms | D009369 | — | C80 | 2 | 2 | 6 | — | 1 | 9 |
| Neuralgia | D009437 | EFO_0009430 | — | — | — | 5 | — | 1 | 6 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | — | 5 | — | — | 5 |
| Infantile spasms | D013036 | EFO_1000643 | G40.82 | — | — | 3 | — | — | 3 |
| Cancer pain | D000072716 | — | G89.3 | — | — | 2 | — | — | 2 |
| Hyperalgesia | D006930 | — | — | — | — | 2 | — | — | 2 |
| Rett syndrome | D015518 | Orphanet_778 | F84.2 | — | — | 2 | — | — | 2 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | 1 | — | — | 1 |
| Cerebral palsy | D002547 | — | G80 | — | — | 1 | — | — | 1 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 2 | — | — | — | 2 |
| Sturge-weber syndrome | D013341 | Orphanet_3205 | Q85.89 | 1 | 2 | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 2 | — | — | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | 1 | 2 |
| Fragile x syndrome | D005600 | — | Q99.2 | — | 2 | — | — | — | 2 |
| Syndrome | D013577 | — | — | — | 2 | — | — | — | 2 |
| Autism spectrum disorder | D000067877 | — | F84.0 | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | — | 1 |
| Drug resistant epilepsy | D000069279 | — | — | 1 | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system diseases | D002493 | — | G96.9 | — | — | — | — | 1 | 1 |
| Brain diseases | D001927 | — | G93.40 | — | — | — | — | 1 | 1 |
| Pregnancy complications | D011248 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cannabidiol |
| INN | cannabidiol |
| Description | Cannabidiol is an cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4. It has a role as a plant metabolite and an antimicrobial agent. It is a member of resorcinols, an olefinic compound and a phytocannabinoid. |
| Classification | Small molecule |
| Drug class | cannabinol derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O |
Identifiers
| PDB | — |
| CAS-ID | 13956-29-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL190461 |
| ChEBI ID | 69478 |
| PubChem CID | 644019 |
| DrugBank | DB09061 |
| UNII ID | 19GBJ60SN5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TRPA1
TRPA1
GPR18
GPR18
TRPV3
TRPV3
CNR1
CNR1
GPR55
GPR55
TRPV2
TRPV2
TRPM8
TRPM8
Organism
Homo sapiens
Gene name
TRPA1
Gene synonyms
ANKTM1
NCBI Gene ID
Protein name
transient receptor potential cation channel subfamily A member 1
Protein synonyms
ankyrin-like with transmembrane domains 1, Ankyrin-like with transmembrane domains protein 1, p120, Transformation-sensitive protein p120, Wasabi receptor
Uniprot ID
Mouse ortholog
Trpa1 (277328)
transient receptor potential cation channel subfamily A member 1 (Q8BLA8)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Epidiolex – Jazz Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 44,095 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
19,182 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use